2022 in Review: After two years of IPOs, the region's publicly traded life sciences firms hit tough times

Only two of the companies that went public since 2020 are trading above their IPO price.

2022 in Review: After two years of IPOs, the region's publicly traded life sciences firms hit tough times
Only two of the companies that went public since 2020 are trading above their IPO price.